Roche announces agreement to acquire PathAI

Roche (RHHBY) announced that it has entered into a definitive merger agreement to acquire PathAI, a U.S.-based company in digital pathology and AI-powered technology for pathology laboratories and the biopharma industry. “This acquisition builds on the successful partnership between Roche and PathAI, established in 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms. Subject to the closing of the transaction, which is expected in the second half of the year, the acquired entity will become part of the Diagnostics division. This acquisition strengthens Roche’s position in Digital Pathology, which is transforming extensive manual workflows into fully automated, AI-driven processes and insights. Digital pathology enables the creation of high-resolution digital images from physical tissue on slides, allowing pathologists to use AI tools to facilitate diagnostic workflows and provide patients with faster results,” Roche stated. The closing of the transaction is subject to customary closing conditions, including antitrust and regulatory approvals and is currently expected in the second half of the year. Under the terms of the agreement, Roche will pay a purchase price of $750M upfront and additional milestone payments of up to $300M.